Key Insights on Gross Profit: Amneal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited

Amneal vs. HUTCHMED: A Decade of Gross Profit Trends

__timestampAmneal Pharmaceuticals, Inc.HUTCHMED (China) Limited
Wednesday, January 1, 201444963400019764000
Thursday, January 1, 201549922600067426000
Friday, January 1, 201659745500059752000
Sunday, January 1, 201752617800065383000
Monday, January 1, 201871640300070165000
Tuesday, January 1, 201935299700044738000
Wednesday, January 1, 202062839300039457000
Friday, January 1, 202176897300097894000
Saturday, January 1, 2022784708000115306000
Sunday, January 1, 2023820565000453552000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Companies: Gross Profit Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited have shown distinct trajectories in their gross profit over the past decade. Amneal Pharmaceuticals, a key player in the U.S. market, has consistently outperformed its counterpart, with a remarkable 82% increase in gross profit from 2014 to 2023. This growth is highlighted by a peak in 2023, where their gross profit reached its highest point.

Conversely, HUTCHMED, a prominent name in China's pharmaceutical sector, has experienced a more volatile journey. Despite a significant surge of over 400% in gross profit by 2023, the company faced fluctuations, particularly between 2019 and 2020. This period marked a downturn, followed by a robust recovery, underscoring the dynamic nature of the global pharmaceutical industry.

These insights not only reflect the companies' financial health but also their strategic positioning in a rapidly evolving market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025